5-Hydroxytryptophan has been previously linked to prodromal phase if not has been linked in PD?

5-Hydroxytryptophan (5-HTP) has been linked to established Parkinson's disease (PD) through clinical and preclinical research focused on managing sleep disturbances, motor complications, and psychiatric symptoms; however, the provided literature does not report a direct link or therapeutic evaluation of 5-HTP specifically during the prodromal phase of the disease.

Clinical and Preclinical Association with Parkinson's Disease

• Sleep Disturbances (RBD): 5-HTP has been investigated as a treatment for REM sleep behavior disorder (RBD) in patients with idiopathic PD. A randomized, double-blind crossover study found that 50 mg of 5-HTP reduced the subjective severity of RBD episodes (Direct, High; PMID: 34403081).
• Levodopa-Induced Dyskinesia (LID): 5-HTP is linked to the reduction of motor complications in PD. Preclinical evidence in hemi-parkinsonian mice demonstrates that 5-HTP significantly reduces abnormal involuntary movements (AIMs) without interfering with the motor efficacy of levodopa (Direct, High; PMID: 36918741). This finding is supported by preliminary human data where PD patients taking 5-HTP showed significant improvement in dyskinesia scores (Direct, High; PMID: 36918741).
• Psychiatric Symptoms: Clinical findings indicate that 5-HTP supplementation is associated with the improvement of depressive symptoms, apathy, and activities of daily living (rated by UPDRS part II) in patients with PD (Direct, High; PMID: 34403081).
• Mechanistic Pathways: In PD models, 5-HTP appears to modulate the AKT/mTOR/S6K and CREB/ΔFosB signaling pathways in the striatum, which are involved in synaptic plasticity and the development of dyskinesia (Direct, High; PMID: 36918741).

Association with the Prodromal Phase

• Evidence Gap for Prodromal 5-HTP: The provided articles do not report evidence or clinical trials specifically evaluating 5-HTP in the prodromal phase of PD (the period before motor symptoms and clinical diagnosis). Clinical studies focused on patients with a confirmed diagnosis of idiopathic PD (Direct, High; PMID: 34403081).
• RBD as a Prodromal Marker: While the literature acknowledges that RBD is a common feature that can present in the context of "pre-motor" (prodromal) symptoms, the specific use of 5-HTP to address these symptoms during the prodromal stage was not established in the provided context (Direct, High; PMID: 34403081).
• Melatonin and Prodromal RBD: Other precursors like melatonin have been studied for clinically isolated RBD (which may be a prodromal phase), but results showed it did not improve clinical status compared to placebo in those specific subjects (Direct, High; PMID: 31674060).

In summary, 5-HTP is established as a therapeutic candidate for sleep and motor complications in diagnosed Parkinson's disease, but its role or association with the prodromal phase remains unreported in the current evidence set.

How do the effects of 5-HTP on REM sleep architecture compare between Parkinson's patients and other sleep disorder models?

What are the specific striatal molecular mechanisms by which 5-HTP regulates AKT/mTOR signaling in the context of levodopa-induced dyskinesia?

What clinical evidence exists regarding the long-term safety and efficacy of 5-HTP supplementation for non-motor symptoms in Parkinson's disease?

Unverified Citations

The following sources failed to support their assigned claims after 3 verification rounds designed to ensure only high-confidence, relevant references are retained:

• PMID:36918741 — ** Psychiatric Symptoms: Clinical findings indicate that 5-HTP supplementation is associated with the improvement o...*
  Failed: conclusion — This paper is a primary research article on mouse models of dyskinesia and its discussion of human clinical data for depression, apathy, and UPDRS II in PD patients is minimal or refers to other studies (like Paper 2) without providing its own data.
• PMID:36918741 — The studies primarily focused on patients with a confirmed diagnosis of idiopathic PD
  Failed: disease — This is a preclinical study using hemi-parkinsonian mice, not humans with idiopathic PD, thus failing the disease context check for a direct claim about patient focus.